scholarly journals Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database

2011 ◽  
pp. 467 ◽  
Author(s):  
Kourtney Davis ◽  
Stephanie Watkins ◽  
Tim Sampson ◽  
Kourtney Davis
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
General Practice Research Database ◽  
Fixed Dose ◽  
Practice Research ◽  
Chronic Obstructive ◽  
Research Database ◽  
Obstructive Pulmonary Disease ◽  
Dose Combination ◽  
The Uk

scholarly journals Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK

BMJ Open ◽  
2018 ◽  
Vol 8 (10) ◽  
pp. e022051
Author(s):  
Jaco Voorham ◽  
Nicolas Roche ◽  
Hicham Benhaddi ◽  
Marianka van der Tol ◽  
Victoria Carter ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Disease Control ◽  
Pulmonary Disease ◽  
Real World ◽  
Fixed Dose ◽  
Chronic Obstructive ◽  
Research Database ◽  
End Points ◽  
Obstructive Pulmonary Disease ◽  
The Uk

ObjectivesBudesonide/formoterol (BF) Spiromax®is an inhaled corticosteroid/long-acting β2-agonist fixed-dose combination (FDC) inhaler, designed to minimise common inhaler errors and provide reliable and consistent dose delivery in asthma and chronic obstructive pulmonary disease (COPD). We evaluated non-inferiority of BF Spiromax after changing from another FDC inhaler, compared with continuing the original inhaler.MethodsPatients with asthma and/or COPD who switched to BF Spiromax were matched (1:3) with non-switchers. Data were obtained from the Optimum Patient Care Research Database and Clinical Practice Research Datalink in the UK. The primary end point was the proportion of patients achieving disease control (using the risk domain control (RDC) algorithm); secondary end points were: exacerbation rate, short-acting β2-agonist (SABA) use and treatment stability (achieved RDC; no maintenance treatment change). Non-inferiority was defined as having 95% CI lower bound above −10%, using conditional logistic regression and adjusted for relevant confounders.ResultsComparing 385 matched patients (asthma 253; COPD 132) who switched to BF Spiromax with 1091 (asthma 743; COPD 348) non-switchers, non-inferiority of BF Spiromax in RDC was demonstrated (adjusted difference: +6.6%; 95% CI –0.3 to 13.5). Among patients with asthma, switchers to BF Spiromax versus BF Turbuhaler®reported fewer exacerbations (adjusted rate ratio (RR) 0.76;95% CI 0.60 to 0.99; p=0.044); were less likely to use high daily doses of SABA (adjusted OR 0.71;95% CI 0.52 to 0.98; p=0.034); used fewer SABA inhalers (adjusted RR 0.92;95% CI 0.86 to 0.99; p=0.019); and were more likely to achieve treatment stability (adjusted OR 1.44;95% CI 1.02 to 2.04; p=0.037). No significant differences in these end points were seen among patients with COPD.ConclusionsAmong UK patients with asthma and COPD, real-world use of BF Spiromax was non-inferior to BF Turbuhaler in terms of disease control. Among patients with asthma, switching to BF Spiromax was associated with reduced exacerbations, reduced SABA use and improved treatment stability versus continuing on BF Turbuhaler.

Sign in / Sign up

Export Citation Format

Share Document